Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Phase 1/2
74
about 1.8 years
18–55
1 site in CA
What this study is about
Researchers are testing whether clemastine fumarate, a drug, can help repair myelin damage in people with multiple sclerosis. The trial will use multi-parametric MRI and UTE MRI to see if clemastine fumarate has a protective or reparative effect on chronic lesions found in patients with relapsing-remitting MS.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Clemastine Fumarate
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Respiratory System Agent (Histamine H1 Receptor Antagonists)
oral (Oral Tablet)
Primary: Change from Baseline in Corpus Callosum Myelin Water Fraction at 3 Months, Change from Baseline in Corpus Callosum Myelin Water Fraction at 6 Months, Change from Baseline in Corpus Callosum T1 Relaxation Time at 3 Months, Change from Baseline in Corpus Callosum T1 Relaxation Time at 6 Months, Change from Baseline in Corpus Callosum UTE Fraction at 3 Months, Change from Baseline in Corpus Callosum UTE Fraction at 6 Months
Secondary: Change from Baseline in Clemastine Tolerability at 3 Months, Change from Baseline in Clemastine Tolerability at 6 Months, Change from Baseline in Corticospinal T1 Relaxation Time at 3 Months, Change from Baseline in Corticospinal Tract Myelin Water Fraction at 3 Months, Change from Baseline in Corticospinal Tract Myelin Water Fraction at 6 Months, Change from Baseline in Corticospinal Tract T1 Relaxation Time at 6 Months, Change from Baseline in Corticospinal Tract UTE Fraction at 3 Months, Change from Baseline in Corticospinal Tract UTE Fraction at 6 Months
Neurology